Education
About Us
Working with TipRanks
Follow Us
SinoMab Bioscience Ltd. (HK:3681)
:3681
3681 Stock Chart & Stats
HK$1.39
-HK$0.01(-1.00%)
At close: 4:00 PM EST
HK$1.39
-HK$0.01(-1.00%)
Day’s Range― - ―
52-Week RangeHK$1.00 - HK$3.76
Previous CloseN/A
Volume24.00K
Average Volume (3M)6.26M
Market Cap
HK$2.68B
Enterprise ValueHK$2.29B
Total Cash (Recent Filing)HK$143.10M
Total Debt (Recent Filing)HK$408.11M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Mar 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,386,638,300
10 Day Avg. Volume8,278,616
30 Day Avg. Volume6,255,789
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.70
Price to Sales (P/S)542.51
P/FCF Ratio-6.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Biologics R&D FocusA concentrated business model around monoclonal antibodies gives SinoMab durable expertise and platform leverage in biologics discovery and development. Specialization supports repeatable R&D processes, potential modular reuse of tech and clearer go-to-market positioning in autoimmune and inflammatory niches.
Recent Top-line GrowthA 48.4% YoY revenue increase signals improving commercial or partnership traction and validates aspects of the company’s development strategy. Sustained top-line growth can support scaling of operations and justify continued R&D investment if converted into more consistent cash generation over the medium term.
Existing Equity CushionA stable equity ratio near 25.6% provides a modest capital buffer against operational volatility. While not conservative, this equity base offers some capacity to absorb losses and supports access to additional funding or strategic partnerships without immediate insolvency risk over the next several months.
Bears Say
High Financial LeverageA debt-to-equity ratio of 2.5 indicates material leverage that raises refinancing and interest-service risks. High leverage constrains strategic flexibility, increases cash burn pressure, and makes funding R&D or clinical programs more dependent on capital markets or dilutive financing, a lasting operational constraint.
Negative Operating Cash FlowPersistently negative operating cash flow and worsening free cash flow mean the business cannot self-fund operations or development. This structural cash deficit forces reliance on external financing, which can be cyclically constrained and dilute shareholders or delay programs if capital access tightens.
Persistent Unprofitability And Weak MarginsConsistent net losses and negative operating margins point to structural profitability challenges. Without sustained margin improvement or material revenue scale, the firm will struggle to reach break-even, maintain R&D spend and service debt simultaneously, implying ongoing strategic and financing risk.
SinoMab Bioscience Ltd. News
3681 FAQ
What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$1.00 and its highest was HK$3.76 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$2.68B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
SinoMab Bioscience Ltd.’s upcoming earnings report date is Mar 23, 2026 which is in 28 days.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Aug 29, 2025. The company reported -HK$0.055 earnings per share for the quarter, missing the consensus estimate of -HK$0.053 by -HK$0.002.
Is SinoMab Bioscience Ltd. overvalued?
According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.055 in its last earnings report, missing expectations of -HK$0.053. Following the earnings report the stock price went up 2.597%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SinoMab Bioscience Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.64%
12-Months-Change
Fundamentals
Return on Equity
-55.33%
Trailing 12-Months
Asset Growth
-12.54%
Trailing 12-Months
Company Description
SinoMab Bioscience Ltd.
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Technical Analysis
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―